Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
The identified prognostic markers are fully explainable and easily implementable in routine practice, facilitating risk stratification upon the cessation of ICI therapy.
Authors
- Reinhard Büttner (ORCID: https://orcid.org/0000-0001-8806-4786)
- Yannick Foerster (ORCID: https://orcid.org/0000-0001-5383-2263)
- Max Schlaak (ORCID: https://orcid.org/0000-0002-1663-8098)
- Doris Helbig (ORCID: https://orcid.org/0000-0002-5841-4631)
- Tilo Biedermann (ORCID: https://orcid.org/0000-0002-5352-5105)
- Ka‐Won Noh (ORCID: https://orcid.org/0000-0002-0041-9560)
- Oana‐Diana Persa (ORCID: https://orcid.org/0000-0003-1469-4464)
- Yuri Tolkach (ORCID: https://orcid.org/0009-0001-7247-7989)
- Vincenzo Mitchell Barroso (ORCID: https://orcid.org/0009-0006-7961-089X)
Institutions
- University of Cologne (DE)
- TUM Klinikum (DE)
- Humboldt-Universität zu Berlin (DE)
- DKFZ-ZMBH Alliance (DE)
- University Hospital Cologne (DE)
- Technical University of Munich (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0889
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05